Back

Variations in the costs of atrial fibrillation: a longitudinal study across 27 European and Central Asian countries

25 August 2023 (17:15 - 17:45)
Organised by: Logo
Congress Presentation Part of: Innovations in public health and health economics (1) Health Economics ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Marjan Walli-Attaei

University of Oxford, Oxford (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
An economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from a German healthcare service payer perspective.
Professor A. Goette (Paderborn, DE)
Abstract Slides Video
Presentation thumbnail
Influence of socioeconomic status on the presence of obstructive coronary artery disease and cardiovascular outcomes in patients undergoing invasive coronary angiography
Doctor J. Chung (Goyang, KR)
Abstract Slides Video
Presentation thumbnail
Quantity and quality of shared decision making incorporation across major international cardiology guidelines
Doctor B. MacDonald (Vancouver, CA)
Abstract Slides Video
Presentation thumbnail
Cardiovascular risk prediction in a New Zealand cohort of patients with known cardiovascular disease - a regional individual patient-level data linkage study
Mr A. Holt (Copenhagen, DK) Miss J. Liang (Auckland, NZ)
Abstract Slides Video

Access the full session

Session thumbnail
Innovations in public health and health economics (1)

The Event

Event poster

ESC Congress 2023

25 August 2023 17:15 CET
You may be interested in
thumbnail
Congress Presentation
The impact of screening-detected atrial fibrillation on quality of life
thumbnail
Congress Presentation
Quality of life in patients with atrial fibrillation and multimorbidity, and their caregivers: results from the AFFIRMO international online survey
thumbnail
Congress Presentation
Quality of life after screening for atrial fibrillation: a substudy from a randomised screening trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources